Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Hanna, M.G.; Badrising, U.A.; Benveniste, O.; Lloyd, T.E.; Needham, M.; Chinoy, H.; ... ; RESILIENT Study Grp (2019)

Article / Letter to editor

• All authors: Hanna, M.G.; Badrising, U.A.; Benveniste, O.; Lloyd, T.E.; Needham, M.; Chinoy, H.; Aoki, M.; Machado, P.M.; Liang, C.; Reardon, K.A.; Visser, M. de; Ascherman, D.P.; Barohn, R.J.; Dimachkie, M.M.; Miller, J.A.L.; Kissel, J.T.; Oskarsson, B.; Joyce, N.C.; Bergh, P. van den; Baets, J.; Bleecker, J.L. de; Karam, C.; David, W.S.; Mirabella, M.; Nations, S.P.; Jung, H.H.; Pegoraro, E.; Maggi, L.; Rodolico, C.; Filosto, M.; Shaibani, A.I.; Sivakumar, K.; Goyal, N.A.; Mori-Yoshimura, M.; Yamashita, S.; Suzuki, N.; Katsuno, M.; Murata, K.; Nodera, H.; Romano, C.D.; Williams, V.S.L.; Vissing, J.; Auberson, L.Z.; Wu, M.; Vera, A. de; Papanicolaou, D.A.; Amato, A.A.; Nishino, I.; RESILIENT Study Grp
• Date: 2019-09-30
• Journal: The Lancet Neurology
• Volume: 18
• Issue: 9
• Pages: 834 - 844